Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during AcuteEarly HIV-1 Infection 英文参考文献.docVIP

下载本文档

6
0
约2.93万字
约 7页
2017-05-13 发布于上海
举报
版权申诉

Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during AcuteEarly HIV-1 Infection 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during AcuteEarly HIV-1 Infection 英文参考文献

SafetyandImmunogenicityofTherapeuticDNA VaccinationinIndividualsTreatedwithAntiretroviral TherapyduringAcute/EarlyHIV-1Infection EricS.Rosenberg1*,BarneyS.Graham2,EllenS.Chan3,RonaldJ.Bosch3,VickiStocker4,JanineMaenza5, MartinMarkowitz6,SusanLittle7,PaulE.Sax8,AnnC.Collier5,GaryNabel2,SuzanneSaindon1 ,Theresa Flynn1,DanielKuritzkes8,DanH.Barouch9,fortheACTGA5187Team 1MassachusettsGeneralHospitalandHarvardMedicalSchool,Boston,Massachusetts,UnitedStatesofAmerica,2VaccineResearchCenter,NationalInstituteofAllergy andInfectiousDiseases,NationalInstitutesofHealth,Bethesda,Maryland,UnitedStatesofAmerica, 3HarvardSchoolofPublicHealth,Boston,Massachusetts,United StatesofAmerica,4SocialandScientificSystems,SilverSpring,Maryland,UnitedStatesofAmerica,5UniversityofWashington,Seattle,Washington,UnitedStatesof America,6AaronDiamondAIDSResearchCenter,RockefellerUniversity,NewYork,NewYork,UnitedStatesofAmerica,7UniversityofCaliforniaSanDiego,SanDiego, California, United States of America, 8Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 9Beth Israel DeaconessMedicalCenter,HarvardMedicalSchool,Boston,Massachusetts,UnitedStatesofAmerica Abstract Background:AneffectivetherapeuticvaccinethatcouldaugmentimmunecontrolofHIV-1replicationmayabrogateor delaytheneedforantiretroviraltherapy.AIDSClinicalTrialsGroup(ACTG)A5187wasaphaseI/II,randomized,placebo- controlled,double-blindedtrialtoevaluatethesafetyandimmunogenicityofanHIV-1DNAvaccine(VRC-HVDNA009-00- VP)insubjectstreatedwithantiretroviraltherapyduringacute/earlyHIV-1infection.(NC Methods: Twenty healthy HIV-1 infected subjects who were treated with antiretroviral therapy during acute/early HIV-1 infectionandhadHIV-1RNA,50copies/mLwererandomizedtoreceiveeithervaccineorplacebo.Theobjectivesofthis study were to evaluate the safety and immunogenicity of the vaccine. Following vaccination, subjects interrupted antiretroviraltreatment,andset-pointHIV-1viralloadsandCD